Lyell Immunopharma (NASDAQ:LYEL) Stock Price Up 3.5% - What's Next?

Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) were up 3.5% during trading on Monday . The company traded as high as $9.03 and last traded at $8.99. Approximately 110,285 shares changed hands during mid-day trading, an increase of 59% from the average daily volume of 69,486 shares. The stock had previously closed at $8.69.

Analyst Upgrades and Downgrades

LYEL has been the subject of a number of analyst reports. HC Wainwright restated a "neutral" rating and issued a $10.00 price target on shares of Lyell Immunopharma in a report on Tuesday. Wall Street Zen upgraded Lyell Immunopharma to a "hold" rating in a report on Friday, June 6th.

Lyell Immunopharma Trading Down 2.0%

The firm has a market capitalization of $132.40 million, a price-to-earnings ratio of -0.36 and a beta of -0.26. The stock has a fifty day moving average of $9.12 and a 200-day moving average of $11.02.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($3.60) earnings per share for the quarter, beating analysts' consensus estimates of ($3.80) by $0.20. Lyell Immunopharma had a negative net margin of 514,649.22% and a negative return on equity of 73.66%. The business had revenue of $0.01 million for the quarter. As a group, equities research analysts forecast that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lyell Immunopharma

Hedge funds and other institutional investors have recently bought and sold shares of the business. Graham Capital Management L.P. bought a new stake in shares of Lyell Immunopharma in the 4th quarter valued at $33,000. RPO LLC bought a new stake in shares of Lyell Immunopharma in the 4th quarter valued at about $42,000. Wells Fargo & Company MN boosted its stake in shares of Lyell Immunopharma by 27.8% during the 4th quarter. Wells Fargo & Company MN now owns 94,320 shares of the company's stock worth $60,000 after acquiring an additional 20,542 shares during the period. Public Employees Retirement System of Ohio acquired a new position in Lyell Immunopharma in the 4th quarter valued at about $64,000. Finally, AQR Capital Management LLC lifted its holdings in Lyell Immunopharma by 773.5% during the 1st quarter. AQR Capital Management LLC now owns 174,279 shares of the company's stock worth $94,000 after purchasing an additional 154,327 shares during the last quarter. 66.05% of the stock is owned by institutional investors and hedge funds.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.